There is described herein a method for predicting response to anti-PD1 based therapy in a subject with cancer, the method comprising: providing a sample of peripheral blood from the subject; adding an IFN-I to the sample; assessing T-cell response to IFN-I stimulation in the peripheral blood sample by measuring the expression of IFN-I stimulated genes; and predicting a better outcome in response to anti-PD1 therapy if the assessment in the previous step indicates T-cell resistance to IFN-I stimulation and predicting a poorer outcome in response to anti-PD1 therapy if the assessment step indicates T-cell responsiveness to IFN-I stimulation.

The invention is directed to methods and systems for carrying out one or more highly multiplexed cellular assays. In some embodiments, one or more channels of a fluidic device are provided with photopolymerizable polymer precursors and cells randomly disposed on a surface, after which positions of cells are measured by a detector, hydrogel chambers are synthesized by photopolymerization to enclose individual cells, and channels are loaded with assay reagents. Assay signals indicative of desired cellular characteristics can be generated for each of the enclosed cells.

The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to a therapeutic combination which comprises a PD-1 antagonist, an ATR inhibitor and a platinating agent.

The disclosure relates to methods and assay that assists in the diagnosis of autoimmune and chronic inflammatory disorders such as systemic lupus erythematosus and rheumatoid arthritis by analyzing drug-responsiveness of an interferon signal in a hematological sample (e.g., blood) obtained from a human subject. The assay involves comparing the interferon signal in a control aliquot of the sample with the same interferon sample in an aliquot that has been exposed to a therapeutic modality (e.g., combined with a drug) that is known to be efficacious to treat the disorder. A significant difference between the interferon signals of the control and treated aliquots that corresponds to a characteristic interferon signature for the disorder indicates that the subject is afflicted with, or is likely to develop, the disorder.

Disclosed herein are methods of identifying biomarkers (such as genes (e.g., RNA or mRNA), proteins, and/or small molecules) that can be used to predict organ or tissue function or dysfunction. In some embodiments, the methods include ex vivo perfusion of the organ or tissue, collection of samples from the organ or tissue (for example, perfusate, fluids produced by the organ (such as bile or urine), or tissue biopsies) and measuring the level of one or more biomarkers in the sample. It is also disclosed herein that an analysis of biomarkers (such as genes (e.g., RNA or mRNA), proteins, and/or small molecules) present in a biological sample from an organ, tissue, or subject can be used to identify whether the organ, tissue, or subject is at risk for (or has) organ dysfunction or organ failure.

Provided are novel IFN- binding molecules of human origin, particularly human-derived anti-IFN- antibodies as well as IFN- binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy are described.

The present disclosure provides a method of identifying a tumor for immunotherapy. The method comprises culturing tumor cells obtained from a subject; exposing the tumor cells to nanoparticles comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer; and measuring interferon-alpha and interleukin 6 (and optionally Chemokine (C-C motif) ligands 4) produced by the tumor cells. A method of treating a subject with cancer also is provided. The method comprises culturing tumor cells from the subject; exposing the tumor cells to the nanoparticles; measuring interferon-alpha and interleukin 6 (and optionally Chemokine (C-C motif) ligands 4) produced by the tumor cells; and administering an immune checkpoint inhibitor to the subject. Any of the methods may also comprise measuring CXCL 10.

The present disclosure is directed to novel biomarkers useful for staging EHV-1 infections and immunity status of horses. This disclosure is further directed to methods of determining EHV-1 infection stage and immunity status of horses using the novel biomarkers.

Provided herein is a method for measuring the levels of chronic inflammaging (SCI) of a subject. In some embodiments, the method may comprise measuring the amount of two or more of the proteins C-X-C motif ligand 9 (CXCL9), TNF-related apoptosis-inducing ligand (TRAIL), interferon gamma (IFNG), eosinophil chemotactic protein (EOTAXIN) and growth-regulated alpha protein (GROA) in a sample (e.g., blood serum) from the subject calculating a score based on the weighted amounts of each of those proteins.